Trials / Completed
CompletedNCT00915083
A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine whether amrubicin is safe and effective in the treatment of patients with advanced solid tumors. The study will assess the pharmacokinetics of the amrubicin and if it has an effect on the heart.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amrubicin | 40mg/m\^2 5 minute IV infusion for 3 consecutive days (21 day cycle) |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2011-05-01
- Completion
- 2011-05-01
- First posted
- 2009-06-05
- Last updated
- 2019-11-01
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00915083. Inclusion in this directory is not an endorsement.